Currently, there is no reported evidence addressing whether and how PARPi-based therapy or chemotherapy could modulate ETAR expression, highlighting a gap in our understanding about the molecular events underpinning ETAR overexpression associated to tumour cell resilience to these treatments in HG-SOC. The gene discussed is UBXN11; the disease is neoplasm.